Skip to main content Accessibility help
×
Home

Reducing psychotropic drug use in people with dementia living in nursing homes

  • Clive Ballard (a1) and Anne Corbett (a1)

Abstract

  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.

Copyright

Corresponding author

References

Hide All
Aalten, P.et al. (2007). Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dementia and Geriatric Cognitive Disorders, 24, 457463.10.1159/000110738
American Psychiatric Association. (2007). Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Available at: http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1679489; last accessed 18 August 2019.
Ballard, C.et al. (2016). Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the Well-Being and Health for People With Dementia (WHELD) Program. The American Journal of Psychiatry, 173, 252262.10.1176/appi.ajp.2015.15010130
Ballard, C.G., Eastwood, C., Gahir, M. and Wilcock, G (1996). A follow up study of depression in the carers of dementia sufferers. BMJ, 312, 947.10.1136/bmj.312.7036.947
Banerjee, S. (2009). The use of antipsychotic medication for people with dementia: time for action…. A Report for the Department of Health (UK). Available at: http://psychrights.org/Research/Digest/NLPs/BanerjeeReportOnGeriatricNeurolepticUse.pdf; last accessed 4 September 2019.
Corbett, A., Smith, J., Creese, B. and Ballard, C. (2012). Treatment of behavioral and psychological symptoms of Alzheimer’s disease. Current Treatment Options in Neurology, 14, 113125.10.1007/s11940-012-0166-9
Coupland, C.A.C., Hill, T., Dening, T., Morriss, R., Moore, M. and Hippisley-Cox, J. (2019). Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Internal Medicine, 179, 10841093.10.1001/jamainternmed.2019.0677
Erdal, A.et al. (2018). Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). Clinical Interventions in Aging, 13, 935946.10.2147/CIA.S161052
Fleisher, A.S.et al. (2011). Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology, 77, 12631271.10.1212/WNL.0b013e318230a16c
Fossey, J.et al. (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ, 332, 756761.10.1136/bmj.38782.575868.7C
Fox, C., Arthur, A. and Ballard, C. (2018). Beyond anti-psychotics: exploring efficacy and harms of Z-drugs for sleep disturbance on the progression of key dementia outcomes. Alzheimer’s Association International Conference, London.10.1016/j.jalz.2018.06.1378
Gilley, D.W., Whalen, M.E., Wilson, R.S. and Bennett, D.A. (1991). Hallucinations and associated factors in Alzheimer’s disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 3, 371376.
Livingston, G.et al. (2017). Dementia prevention, intervention, and care. The Lancet, 390, 26732734.10.1016/S0140-6736(17)31363-6
Lyketsos, C.G.et al. (2001). Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. International Journal of Geriatric Psychiatry, 16, 10431053.10.1002/gps.448
Maust, D.T.et al. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry, 72, 438445.10.1001/jamapsychiatry.2014.3018
Medicines and Healthcare Products Regulatory Agency. (2014). Antipsychotics: initiative to reduce prescribing to older people with dementia. Available at: https://www.gov.uk/drug-safety-update/antipsychotics-initiative-to-reduce-prescribing-to-older-people-with-dementia; last accessed 4 September 2019.
Muñiz, R.et al. (2019). The “CHROME criteria”: tool to optimize and audit prescription quality of psychotropic medications in institutionalized people with dementia. International Psychogeriatrics, 32, 315–324.10.1017/S104161021900111X
Porsteinsson, A.P.et al. (2014). Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA: The Journal of the American Medical Association, 311, 682691.10.1001/jama.2014.93
Scarmeas, N.et al. (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Archives of Neurology, 62, 16011608.10.1001/archneur.62.10.1601
Wadsworth, L.P.et al. (2012) Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dementia and Geriatric Cognitive Disorders, 34, 96111.10.1159/000342119

Reducing psychotropic drug use in people with dementia living in nursing homes

  • Clive Ballard (a1) and Anne Corbett (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.